Comparing Tegoprazan and PPI-Based Triple Therapies with Bismuth for Helicobacter Pylori Eradication in Adults over 14 Days

What this Trial Is About

Researchers are investigating the effectiveness and treatment compliance of tegoprazan compared to proton pump inhibitors PPIs in the first-line treatment of Helicobacter pylori infection by adding bismuth to the therapy. This study addresses the need to improve eradication rates amid antibiotic resistance, building on previous findings that suggest bismuth addition increases success rates. The trial focuses on adults aged 20 to 80 years undergoing treatment for H. pylori infection. Participants receive one of four treatment regimens combining either standard-dose PPI or tegoprazan with amoxicillin, clarithromycin, and tripotassium dicitrate bismuthate DENOL over 14 days. The dosing varies between twice daily and four times daily schedules for amoxicillin. The study compares the eradication success rates and treatment compliance between these groups to determine the potential benefits of tegoprazan-based therapy with bismuth addition. During the study, participants undergo gastroscopy and H. pylori testing with pathological analysis to confirm infection status. Researchers monitor eradication rates, treatment compliance, and drug-related adverse events over a 6-week period following therapy. The study is observational, and participants will be followed through the treatment and evaluation phases until study completion in 2026.

Tegoprazan- Versus PPI-based H. Pylori Eradication